CN118103405A - 可激活多肽复合物 - Google Patents

可激活多肽复合物 Download PDF

Info

Publication number
CN118103405A
CN118103405A CN202280069525.3A CN202280069525A CN118103405A CN 118103405 A CN118103405 A CN 118103405A CN 202280069525 A CN202280069525 A CN 202280069525A CN 118103405 A CN118103405 A CN 118103405A
Authority
CN
China
Prior art keywords
seq
amino acid
acid sequence
activatable
polypeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280069525.3A
Other languages
English (en)
Chinese (zh)
Inventor
L·M·布斯塔尼
M·M·帕德洪加特
E·A·M·福克斯
S·米特拉
W·M·卡瓦诺
R·布里安特
J·L·史蒂文斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Emgen Ltd
Cytomx Therapeutics Inc
Original Assignee
Emgen Ltd
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emgen Ltd, Cytomx Therapeutics Inc filed Critical Emgen Ltd
Publication of CN118103405A publication Critical patent/CN118103405A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280069525.3A 2021-10-15 2022-10-14 可激活多肽复合物 Pending CN118103405A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163256410P 2021-10-15 2021-10-15
US63/256,410 2021-10-15
US202263370895P 2022-08-09 2022-08-09
US63/370,895 2022-08-09
PCT/US2022/078157 WO2023064927A1 (en) 2021-10-15 2022-10-14 Activatable polypeptide complex

Publications (1)

Publication Number Publication Date
CN118103405A true CN118103405A (zh) 2024-05-28

Family

ID=84331755

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280069525.3A Pending CN118103405A (zh) 2021-10-15 2022-10-14 可激活多肽复合物

Country Status (17)

Country Link
US (1) US20230183382A1 (cg-RX-API-DMAC7.html)
EP (1) EP4416180A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024539650A (cg-RX-API-DMAC7.html)
KR (1) KR20240115809A (cg-RX-API-DMAC7.html)
CN (1) CN118103405A (cg-RX-API-DMAC7.html)
AU (1) AU2022365116A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234609A1 (cg-RX-API-DMAC7.html)
CL (1) CL2024001180A1 (cg-RX-API-DMAC7.html)
CO (1) CO2024006111A2 (cg-RX-API-DMAC7.html)
CR (1) CR20240204A (cg-RX-API-DMAC7.html)
IL (1) IL312145A (cg-RX-API-DMAC7.html)
JO (1) JOP20240086A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004563A (cg-RX-API-DMAC7.html)
PE (1) PE20241343A1 (cg-RX-API-DMAC7.html)
TW (1) TW202330611A (cg-RX-API-DMAC7.html)
UY (1) UY39984A (cg-RX-API-DMAC7.html)
WO (1) WO2023064927A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4496816A1 (en) * 2022-03-23 2025-01-29 CytomX Therapeutics, Inc. Activatable antigen-binding protein constructs and uses of the same
WO2025235515A1 (en) 2024-05-07 2025-11-13 Cytomx Therapeutics, Inc. Activatable polypeptide complex formulations
WO2026002279A1 (en) * 2024-06-28 2026-01-02 Vibrant Pharma Limited Mask peptide, cleavable substrate, multispecific antibodies and uses thereof

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US6174666B1 (en) 1992-03-27 2001-01-16 The United States Of America As Represented By The Department Of Health And Human Services Method of eliminating inhibitory/instability regions from mRNA
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
GB9701425D0 (en) 1997-01-24 1997-03-12 Bioinvent Int Ab A method for in vitro molecular evolution of protein function
IL136574A0 (en) 1997-12-08 2001-06-14 California Inst Of Techn A method for forming a polynucleotide of desired properties
AU1456101A (en) 1999-11-03 2001-05-14 Maxygen, Inc. Antibody diversity generation
WO2008119567A2 (en) * 2007-04-03 2008-10-09 Micromet Ag Cross-species-specific cd3-epsilon binding domain
EP2190861A4 (en) 2007-08-22 2011-03-30 Univ California ACTIVE BINDING POLYPEPTIDES AND METHOD FOR THEIR IDENTIFICATION AND USE
EP3543256A1 (en) 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
PE20150605A1 (es) 2012-04-27 2015-05-28 Cytomx Therapeutics Inc Anticuerpos activables que se unen al receptor del factor de crecimiento epidermico
US20140302037A1 (en) * 2013-03-15 2014-10-09 Amgen Inc. BISPECIFIC-Fc MOLECULES
JP6693872B2 (ja) 2013-07-25 2020-05-13 シトムクス セラピューティクス,インコーポレイティド 多重特異性抗体、多重特異性活性化可能抗体、及びそれらの使用方法
KR20250051130A (ko) 2013-09-25 2025-04-16 싸이톰스 테라퓨틱스, 인크. 매트릭스 메탈로프로테이나제 기질 및 다른 절단성 모이어티 및 이의 사용 방법
EP3628328B1 (en) 2014-01-31 2022-09-14 Cytomx Therapeutics Inc. Matriptase and u-plasminogen activator substrates and other cleavable moieties and methods of use thereof
CA2955947A1 (en) 2014-07-25 2016-01-28 Cytomx Therapeutics, Inc. Anti-cd3 antibodies, activatable anti-cd3 antibodies, multispecific anti-cd3 antibodies, multispecific activatable anti-cd3 antibodies, and methods of using the same
IL300408B2 (en) 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
TWI744242B (zh) * 2015-07-31 2021-11-01 德商安美基研究(慕尼黑)公司 Egfrviii及cd3抗體構築體
WO2017162587A1 (en) * 2016-03-22 2017-09-28 F. Hoffmann-La Roche Ag Protease-activated t cell bispecific molecules
CA3032430A1 (en) * 2016-08-16 2018-02-22 Epimab Biotherapeutics, Inc. Monovalent asymmetric tandem fab bispecific antibodies
WO2018045110A1 (en) * 2016-08-30 2018-03-08 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
CN111247171A (zh) 2017-10-14 2020-06-05 西托姆克斯治疗公司 抗体、可活化抗体、双特异性抗体和双特异性可活化抗体及其使用方法
US20210324088A1 (en) 2018-05-02 2021-10-21 Cytomx Therapeutics, Inc. Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof
EP4126248A4 (en) * 2020-03-31 2024-07-10 Fred Hutchinson Cancer Center HUMAN ANTI-CD33 ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
JP2024539650A (ja) 2024-10-29
CL2024001180A1 (es) 2024-10-04
PE20241343A1 (es) 2024-07-03
US20230183382A1 (en) 2023-06-15
IL312145A (en) 2024-06-01
CO2024006111A2 (es) 2024-06-27
MX2024004563A (es) 2024-04-30
CR20240204A (es) 2024-09-13
EP4416180A1 (en) 2024-08-21
WO2023064927A9 (en) 2024-05-16
KR20240115809A (ko) 2024-07-26
WO2023064927A1 (en) 2023-04-20
CA3234609A1 (en) 2023-04-20
UY39984A (es) 2023-07-31
AU2022365116A1 (en) 2024-05-02
TW202330611A (zh) 2023-08-01
JOP20240086A1 (ar) 2024-04-14

Similar Documents

Publication Publication Date Title
CN112955461B (zh) 针对Her2和CD3的同源二聚体型双特异性抗体及其用途
KR102412023B1 (ko) 레날리도마이드 또는 포말리도마이드 및 cd38 항체-감쇠 인터페론-알파 구성체의 조합, 및 이의 용도
JP7489922B2 (ja) 抗ox40抗体及び使用方法
US20220025046A1 (en) Bispecific antigen binding molecules targeting ox40 and fap
US20230174995A1 (en) Activatable polypeptide complex
KR20180081606A (ko) 암 치료에서의 단독의, 또는 면역 자극제와 병용한, fgfr2 억제제
US20230183382A1 (en) Activatable polypeptide complex
US20230212291A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
WO2023064955A1 (en) Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
WO2021098757A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
US20250243283A1 (en) Activatable anti-cd3, anti-egfr, heteromultimeric bispecific polypeptide complex
WO2021098750A1 (en) Methods of cancer treatment with anti-ox40 antibody in comibinaiton with tlr agonists
WO2021098758A1 (en) Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
CN118103406A (zh) 可激活多肽复合物
WO2020225456A1 (en) Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
WO2025235515A1 (en) Activatable polypeptide complex formulations

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination